Bcl-2 Inhibitors Induce Apoptosis via Segmented Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Designing potent, non-peptide small molecule inhibitors of Bcl-2/Bcl-xL remains a challenge due to the large and hydrophobic binding interfaces, conformational flexibility of the proteins, and the need for specific binding grooves, which has hindered the development of effective cancer therapeutics.
Innovation Solution
Development of new class of potent Bcl-2/Bcl-xL inhibitors with specific structural formulas that bind to Bcl-2 and/or Bcl-xL with high affinity (Ki values <1 nM), inducing apoptosis in cancer cells and demonstrating robust antitumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-peptide small molecule inhibitors are designed to block Bcl-2/Bcl-xL binding groove, then apoptosis induction in cancer cells is achieved, but the inhibitors have weak to modest affinities and lack well-defined mode of action
Solution Approach 1:
The inhibitor molecule is divided into distinct functional segments: a hydrophobic region that inserts into the binding groove, a polar region that forms specific hydrogen bonds with residues in the groove, and linkers that connect these regions. This segmentation allows each part to contribute specifically to binding affinity and selectivity, resolving the contradiction between achieving reliable apoptosis induction and maintaining precise binding affinity.
Solution Approach 2:
The inhibitor exhibits different local chemical properties at different regions: hydrophobic aromatic rings at one end for inserting into the hydrophobic pocket, polar amide and hydroxyl groups at another end for forming hydrogen bonds with specific residues like Ser143 and Thr145. This local quality differentiation enables the molecule to achieve both strong binding affinity and specific mode of action, overcoming the weakness of previous non-peptide inhibitors.
2Manufacturing precision
If inhibitors are designed with high affinity for Bcl-2/Bcl-xL, then potency increases, but the large and hydrophobic binding interfaces make design challenging
Solution Approach 1:
The design extracts only the essential binding elements from the complex Bcl-2/Bcl-xL interface: a hydrophobic aromatic segment to occupy the hydrophobic pocket and a polar segment to form key hydrogen bonds. By taking out only these critical interaction elements rather than attempting to match the entire large interface, the inhibitor achieves high binding affinity with a manageable molecular structure, resolving the contradiction between potency and structural complexity.
Solution Approach 2:
The inhibitor approaches the binding problem from a different dimensional perspective by using a linear peptidomimetic structure with distinct N-terminal and C-terminal regions rather than attempting to create a three-dimensional structure that mimics the natural BH3 domain. This dimensional simplification allows high affinity binding while reducing the perceived structural complexity.
3Object-affected harmful factors
If specific binding grooves are targeted for high potency, then cancer cell selectivity improves, but conformational flexibility of Bcl-2/Bcl-xL proteins hinders inhibitor design
Solution Approach 1:
The inhibitor design incorporates pre-organized rigid structural elements (aromatic rings, amide bonds in specific geometries) that are predetermined to fit the Bcl-2/Bcl-xL binding groove conformation. This preliminary structuring compensates for the target protein's conformational flexibility by locking the inhibitor in the optimal binding pose, thereby achieving cancer cell selectivity despite the protein's structural dynamics.
Solution Approach 2:
The inhibitor utilizes changes in local conformational parameters along its backbone, with rigid aromatic segments alternating with flexible linker regions. This parameter variation allows the molecule to adapt to the conformational flexibility of Bcl-2/Bcl-xL while maintaining overall structural integrity for specific binding, thus achieving both cancer cell selectivity and accommodating protein flexibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively induce apoptosis in cancer cells and show strong antitumor activity, addressing the limitations of existing inhibitors by achieving high specificity and potency comparable to ABT-737 and ABT-263.
Implementation Method 1
The present compounds are potent inhibitors of Bcl-2/Bcl-xL activation... ABT-737 and ABT-263 bind to Bcl-2, Bcl-xL, and Bcl-w with very high affinities
Implementation Method 2
Bcl-2 and Bcl-xL proteins inhibit apoptosis by heterodimerization with pro-apoptotic Bcl-2 family proteins... Inhibiting Bcl-2 activity in cancer cells can reduce chemotherapeutic resistance and increase the killing of cancer cells
Data Source
AI summary
Inhibitors of Bcl-2/Bcl-xL and compositions containing the same are disclosed. Methods of using the Bcl-2/Bcl-xL inhibitors in the treatment of diseases and conditions wherein inhibition of Bcl-2/Bcl-xL provides a benefit, like cancers, also are disclosed.